Most treatment-emergent adverse events (TEAEs) were mild and were GI-related
When used in patients experiencing lower GI symptoms while taking GLP-1 medications, ARM allows clinicians to: Differentiate between drug-related motility effects and true pelvic floor dysfunction Quantify the severity of anorectal dysfunction to support diagnosis and treatment planning Establish a baseline prior to initiating biofeedback or behavioral therapy Monitor progress if conservative management is pursued Persistent Constipation in GLP-1 Users ARM can determine if dyssynergic defecation is contributing to delayed evacuation, guiding appropriate therapy beyond simply adjusting medication
G., Emma, F., Sorino, P., De, Palo T., Lavoratti, G., Turrini, Dertenois L., Cassanello, M., Cerone, R., and Perfumo, F
Ji B, Maeda J, Higuchi M, Inoue K, Akita H, Harashima H, Suhara T
Whether an approved version of retatrutide will offer flexibility to maintain at intermediate doses as semaglutide and tirzepatide do will depend on the FDA-approved prescribing information
